StreetInsider.com News Articles

Form 4 InMed Pharmaceuticals For: Oct 16 Filed by: Schneeberger Daniel

Tue, 20 Oct 2026 17:31:00 -0400

si-local-file:///var/storage/secattach/20261020/27211374.html

Form 4 InMed Pharmaceuticals For: Oct 13 Filed by: Schneeberger Daniel

Thu, 15 Oct 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20261015/27193897.html

Form 4 InMed Pharmaceuticals For: Oct 06 Filed by: Schneeberger Daniel

Thu, 08 Oct 2026 18:28:00 -0400

si-local-file:///var/storage/secattach/20261008/27167901.html

Form SCHEDULE 13G/A InMed Pharmaceuticals Filed by: ADAR1 Capital Management, LLC

Wed, 07 Oct 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20261007/27162133.html

Form 4 InMed Pharmaceuticals For: Oct 01 Filed by: Schneeberger Daniel

Mon, 05 Oct 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20261005/27149913.html

Form EFFECT InMed Pharmaceuticals

Fri, 02 Oct 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20261002/27138593.html

Form 424B3 InMed Pharmaceuticals

Thu, 01 Oct 2026 16:18:00 -0400

http://archive.fast-edgar.com/20261001/AS22V22GZC2RVTZ2222B2ZYSDJA9EZ223282

Filed on: October 1, 2026

Form S-4/A InMed Pharmaceuticals

Tue, 29 Sep 2026 17:08:00 -0400

http://archive.fast-edgar.com/20260929/AS22V62GZ22RVZZZ272B2ZYSDJA9OZ22Z282

Filed on: September 29, 2026

Form 8-K InMed Pharmaceuticals For: Sep 16

Fri, 18 Sep 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260918/27081277.html

InMed Pharmaceuticals gets Nasdaq equity deficiency notice

Fri, 18 Sep 2026 16:47:12 -0400

InMed Pharmaceuticals Inc. (NASDAQ: INM) has received a notice from Nasdaq's Listing Qualifications Department stating that the company's shareholders' equity fell below the minimum threshold required for continued listing on the Nasdaq Capital Market.

According to the company's Annual Report on Form 10-K for the fiscal year ended June 30, 2026, InMed reported shareholders' equity of $1,075,007, below the $2,500,000 minimum required under Nasdaq Listing Rule 5550(b)(1).

InMed attributed the decline primarily to transaction-related expenses connected to a previously announced Agreement and Plan of Merger and Reorganization dated May 19, 2026, with Mentari Therapeutics, Inc. Additional contributing factors included costs related to

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance

Fri, 18 Sep 2026 16:45:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that the shareholders' equity of $1,075,007 as reported in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2026, was below the minimum shareholders' equity of $2,500,000 required for continued listing on The Nasdaq Capital Market

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance

Fri, 18 Sep 2026 16:45:00 -0400

Form 4 InMed Pharmaceuticals For: Sep 14 Filed by: Schneeberger Daniel

Wed, 16 Sep 2026 18:58:00 -0400

si-local-file:///var/storage/secattach/20260916/27071444.html

InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update

Wed, 09 Sep 2026 16:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its fiscal year ended June 30, 2026.

The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2026, are available at www.inmedpharma.com, www.sedarplus.ca and www.sec.gov.

"This has been an important year for InMed as we position InMed for its next phase through the proposed merger with Mentari Therapeutics, Inc.,"

InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update

Wed, 09 Sep 2026 16:30:00 -0400

The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2026, are available at www.inmedpharma.com, www.sedarplus.ca and www.sec.gov.

"This has been an important year for InMed as we position InMed for its next phase through the proposed merger with Mentari Therapeutics, Inc.,"

Form SCHEDULE 13G InMed Pharmaceuticals Filed by: Ikarian Capital, LLC

Fri, 14 Aug 2026 21:12:00 -0400

si-local-file:///var/storage/secattach/20260814/26933302.html

Form SCHEDULE 13G InMed Pharmaceuticals Filed by: Ikarian Capital, LLC

Fri, 14 Aug 2026 21:12:00 -0400

si-local-file:///var/storage/secattach/20260814/26933302.html

Form 425 InMed Pharmaceuticals Filed by: InMed Pharmaceuticals Inc.

Wed, 22 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260722/26802171.html

Form 425 InMed Pharmaceuticals Filed by: InMed Pharmaceuticals Inc.

Wed, 22 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260722/26802171.html

Form 425 InMed Pharmaceuticals Filed by: InMed Pharmaceuticals Inc.

Wed, 22 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260722/26802135.html

Form 425 InMed Pharmaceuticals Filed by: InMed Pharmaceuticals Inc.

Wed, 22 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260722/26802135.html

Form 8-K InMed Pharmaceuticals For: Jul 22

Wed, 22 Jul 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260722/26802066.html

Form 8-K InMed Pharmaceuticals For: Jul 22

Wed, 22 Jul 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260722/26802066.html

Mentari Therapeutics raises $200M in private placement tied to INM merger

Wed, 22 Jul 2026 07:00:28 -0400

Mentari Therapeutics, Inc., a privately held biotechnology company focused on migraine prevention, announced a $200 million private placement consisting of common stock and pre-funded warrants, according to a press release dated July 22, 2026.

The financing round includes investors such as Fairmount, ADAR1 Capital Management, Venrock Healthcare Capital Partners, Janus Henderson Investors, Blackstone Multi-Asset Investing, RTW Investments, Deep Track Capital, BB Biotech, and others. Jefferies, TD Cowen, Stifel, and Guggenheim Securities acted as placement agents.

The private placement is expected to close immediately before the completion of Mentari's planned merger with InMed Pharmaceuticals, Inc. (NASDAQ: INM) and concurrently with a previously announced

Mentari Therapeutics raises $200M in private placement tied to INM merger

Wed, 22 Jul 2026 07:00:28 -0400

The private placement is expected to close immediately before the completion of Mentari's planned merger with InMed Pharmaceuticals, Inc. (NASDAQ: INM) and concurrently with a previously announced